Carson Block of Muddy Waters Capital makes the short case on Chinook Therapeutics (KDNY). Muddy Waters argues that, upon further examination of trial data, its primary candidate for kidney disease, atrasentan, not only is inefficacious, but also shows an alarming rate of patient heart failure. Muddy Waters believes that AbbVie and Chinook have manipulated and misrepresented atrasentan trial data in order obscure its myriad problems.